BETA
Your AI-Trained Oncology Knowledge Connection!
July 10th 2025
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.
In the MIDAS trial, ASCT showed no added MRD benefit over Isa-KRd in newly diagnosed myeloma, raising questions about transplant timing.
July 9th 2025
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.
July 8th 2025
During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Greenlights Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Linvoseltamab represents a promising new approach to treating multiple myeloma through immune-based therapy.
Read More
Lack of Comparative Trials in R/R MM Complicates Treatment Selection
Expanding Bispecific Antibody Use in Community Oncology Practice
During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for teclistamab in myeloma.
Dr Leleu on SC Isatuximab via On-Body Injector in R/R Multiple Myeloma
Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.
Optimizing Supportive Care for Talquetamab Adverse Events in Myeloma
During a live event, Alfred L. Garfall, MD, discussed the dose adjustments and supportive care for toxicities seen with talquetamab in multiple myeloma.
Combinations For Transplant-Ineligible NDMM Need Careful Monitoring
During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma and the need for monitoring for neuropathy with bortezomib.
Anito-Cel Shows Durable Responses in Heavily Pretreated R/R Multiple Myeloma
New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.
Triple Combination Shows Early Promise in Newly Diagnosed, Transplant-Ineligible MM
Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating newly diagnosed multiple myeloma.
Selinexor Shows Promise for Enhancing CAR T Outcomes in Myeloma
Quarterly MRD Monitoring After Daratumumab Extends Time to Relapse in Myeloma
Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved patient outcomes.
Isa-KRd Deepens MRD Negativity in High-Risk NDMM
The IsKia trial reveals that isatuximab enhances MRD negativity in newly diagnosed multiple myeloma, especially in high-risk patients.
Selinexor Shows Potential Role in PI-Naive Relapsed Multiple Myeloma
During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and beyond in patients with multiple myeloma.
Cilta-Cel Bests SOC in Refractory Multiple Myeloma
Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.
Subcutaneous Isatuximab With On-Body Injector: A Patient-Preferred Alternative
The IRAKLIA study reveals that subcutaneous isatuximab offers comparable efficacy and improved patient satisfaction over intravenous administration for multiple myeloma.
Talquetamab Plus Cetrelimab Shows Promising Early Data in R/R Myeloma
Linvoseltamab/Bortezomib Shows Consistent Safety in Relapsed/Refractory Multiple Myeloma
Linvoseltamab plus bortezomib showed a manageable safety profile and 85% ORR in relapsed/refractory multiple myeloma, with few discontinuations.
Coordination Is Essential During and After Referral for CAR T in Myeloma
During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy toxicity and how to coordinate with CAR T providers.
Bridging and BCMA Exposure Impact Ide-Cel Outcomes in Multiple Myeloma
During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients receiving ide-cel in terms of bridging therapy, quality of life, and prior BCMA therapy.
BPd Combo Improves PFS & Response in High-Risk Relapsed/Refractory Myeloma
Combination therapy with BPd shows significant progression-free survival benefits in relapsed/refractory multiple myeloma patients with high-risk cytogenetic abnormalities.
Frailty Is a Key Consideration in Transplant-Ineligible NDMM
During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed multiple myeloma.
Novel Trispecific Antibody Delivers Efficacy and Safety in Myeloma
JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple myeloma.
DKRd Improves Efficacy in Newly Diagnosed Multiple Myeloma
Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and progression-free survival in recent clinical trials.
ASCT Fails to Improve MRD Negativity After Isa-KRd in Multiple Myeloma
A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity.
Cilta-cel Shows 5-Year Progression-Free Survival in Multiple Myeloma
A single cilta-cel infusion led to 33% of heavily pretreated relapsed/refractory multiple myeloma patients remaining progression-free at 5+ years.
D-VRd Improves PFS & MRD Negativity in Transplant-Eligible NDMM
D-VRd Improves Responses & Survival in Transplant-Ineligible NDMM
Talquetamab Shows Durable Responses in Relapsed/Refractory Multiple Myeloma
Extended follow-up of MonumenTAL-1 shows talquetamab-tgvs yields durable ORRs and promising survival outcomes in relapsed/refractory multiple myeloma, with a tolerable safety profile.
Social, Logistical Barriers Limit Use of CAR T-Cell Therapy in Myeloma
During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring patients for CAR T-cell therapy.
PFS Benefit of Ide-cel in Myeloma Maintained in Higher-Risk Population
During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.
Managing CRS and Infections Associated With Talquetamab in Myeloma
During a live event, Naresh Bumma, MD, discussed CRS, oral and skin toxicities, and low discontinuation rates with talquetamab in multiple myeloma.